Blood Res 2020; 55(4): 206-212  https://doi.org/10.5045/br.2020.2020158
Safety and efficacy analysis of ibrutinib in 32 patients with CLL and various B-cell lymphomas: real-world data from a single-center study in Turkey
Mesut Göçer, Erdal Kurtoğlu
Department of Hematology, Antalya Training and Research Hospital, Antalya, Turkey
Correspondence to: Mesut Göçer, M.D.
Department of Hematology, Antalya Training and Research Hospital, Antalya 07055, Turkey
E-mail: gocermesut@gmail.com
Received: July 3, 2020; Revised: August 13, 2020; Accepted: October 8, 2020; Published online: December 11, 2020.
© The Korean Journal of Hematology. All rights reserved.

Abstract
Background
Ibrutinib is an oral irreversible Bruton’s tyrosine kinase inhibitor. Here, we demonstrate the efficacy and safety of ibrutinib using real-life data from patients with marginal zone lymphoma (MZL), diffuse large B-cell lymphoma (DLBCL), Waldenström macroglobulinemia (WM), and follicular lymphoma (FL), especially in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).
Methods
This is a retrospective, observational, non-interventional, and single-center study on 32 patients who received ibrutinib treatment between January 2017 and March 2020 regardless of their diagnosis.
Results
Of the 32 patients, 11 had CLL and 21 had other B-cell lymphomas. Patients with CLL were prescribed ibrutinib for a median of 4 months (range, 2-18). In this group, diarrhea was observed in 3 (27.3%), pneumonia in 3 (27.3%), and thrombocytopenia and/or neutropenia in 2 (18.2%) patients. The overall response rate (ORR) was 85.6 % [28.5 % complete response (CR) and 57.1 % partial response (PR)] in the final response assessment during treatment with ibrutinib. Among other types of B-cell lymphoma, seven (33.4%) of the 21 patients were diagnosed with MCL, 5 (23.8%) with DLBCL, 4 (19.0%) with MZL, 3 (14.3%) with WM, and 2 (9.5%) with FL, upon follow-up. The median treatment duration was 4 months (range, 1-28) in this group. The most common adverse event was diarrhea: 8 (38.1%) patients. The ORR was 66.6% (20.0% CR and 46.6% PR) in the final response assessment during the treatment.
Conclusion
Ibrutinib is a good treatment option for CLL and other B-cell lymphomas, with an acceptable side effect profile, and high and promising CR/PR response rates. Ibrutinib treatment at an early stage decreases the burden of cytotoxic therapy in fragile patients, thereby, increasing their quality of life.
Keywords: Ibrutinib, Bruton’s tyrosine kinase, B-cell lymphoma, Chronic lymphocytic leukemia
INTRODUCTION

The B-cell receptor (BCR) is a transmembrane receptor that controls the differentiation and function of normal B-cells, which is located on the cell surface of B-lymphocytes [1]. Bruton’s tyrosine kinase (BTK) is a membrane-proximal tyrosine kinase that plays a crucial role in the BCR signaling cascade [2]. The dysregulation of BCR signaling (dysregulated BTK activity) promotes the cancer cells to evade apoptosis, resulting in proliferation and survival of malignant B-cells [3]. Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults, characterized by progressive accumulation of monoclonal B-lymphocytes. Non-Hodgkin lymphomas (NHLs) consist of a complex group of cancers arising primarily from B-lymphocytes (85% of cases) [4].

Ibrutinib is an irreversible BTK inhibitor for oral use [5]. It covalently binds to the cysteine-481 amino acid of the BTK enzyme; thereby, preventing the migration and proliferation of malignant B-cells. However, it also decreases the lifespan of B-cells [3]. Several studies have proven the efficacy of ibrutinib as a therapeutic agent in many NHLs, including mantle cell lymphoma (MCL), Waldenström macroglobulinemia (WM), marginal zone lymphoma (MZL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL), especially CLL [6-11].

Ibrutinib has a highly selective inhibitory effect towards BTK; however, it also has affinity for several kinases, such as IL2-inducible T-cell kinase, B-cell/myeloid kinase, TEC, epidermal growth factor, and Janus kinase-3 [12]. Its effects on these kinases, apart from BTK, is responsible for several side effects [13-15]. Generally, ibrutinib is a well-tolerated drug with acceptable side effects [16]. However, treatment may have to be discontinued or withdrawn in several patients due to side effects, including cytopenia, infection, bleeding, atrial fibrillation (AF), and pneumonia [16, 17].

The major advantage of ibrutinib is that it can be used orally and has a relatively acceptable side effect profile. However, it is the preferred treatment agent in all age groups as it has a broad indication, especially in older patients who cannot tolerate cytotoxic therapy. Here, we report real-life data from 32 patients with B-cell malignancy who were treated with ibrutinib, and compare them with the data from published literature, to study the efficacy and side effect profile of ibrutinib.

MATERIALS AND METHODS

Study design

In this retrospective, observational, non-interventional, and single-center study, we aimed to evaluate the efficacy and side effect profile of ibrutinib. Adult patients with B-cell malignancies, including relapse/refractory CLL, MCL, MZL, WM, DLBCL, and FL, who were followed up in our clinic, were included in the study. Patients with CLL and WM were prescribed 420 mg of ibrutinib/day, whereas other patients with NHL were prescribed 560 mg of ibrutinib/day.

Patients who had received treatment with ibrutinib, or continued to receive it between January 2017 and March 2020 were included in the study. The hospital management and ethics committee approved the use of patient data. The study was conducted in accordance with the Declaration of Helsinki. The patient data on demographic features, genetic characteristics, previous treatments and numbers, doses of ibrutinib, reasons for drug withdrawal or discontinuation, and side effects, were noted. The end points of the study were the overall response rate (ORR), overall survival (OS), progression-free survival (PFS), and safety of ibrutinib. The criteria under the International Working Group on CLL was used to evaluate the response in patients with CLL, and the criteria under the Lugano classification for response assessment in lymphoma was used for the other lymphomas [18, 19].

Statistical analysis

Descriptive statistics were used to study each of the defined cohorts. Continuous variables were expressed as mean, median, and ranges, whereas categorical variables were presented as frequencies and percentages. Survival functions (PFS and OS) were estimated using the Kaplan–Meier method, and were compared using the log-rank test. All statistical analyses were performed using IBM SPSS, version 15.0 (SPSS Inc., Chicago, IL, USA). The P-value for statistical significance was set at P<0.05.

RESULTS

All the files of the 32 patients treated with ibrutinib who were followed up in our clinic between January 2017 and March 2020, were evaluated retrospectively. Of the 32 patients, 11 had CLL and 21 had other B-cell lymphomas. We examined our patients in two groups: CLL and other B-cell lymphomas, for better comparison with the other studies.

Of the 11 patients with CLL, 7 (63.4%) were male and the median age was 65 years (51–80 yr). The demographic and clinical characteristics of the patients are shown in Table 1. When evaluated at the initiation of treatment with ibrutinib, only 1 patient (9.1%) had an Eastern Cooperative Oncology Group (ECOG) performance score ≥3; 7 (63.6%) patients were at stage 3 or 4 under the Rai classification; 2 (18.2%) patients had bulky lesions (>10 cm). The del17p (deletion17p) mutation test was performed in all patients with CLL, and was positive in 4 (36.4%) patients. Hypertension (36.4%) was the most prevalent comorbidity in patients with CLL. Only 1 (9.1%) patient had not received any previous treatment with ibrutinib, whereas 2 (18.2%) patients received 4 or more treatment regimens. Rituximab, fludarabine, and cyclophosphamide (R-FC) was the most commonly used chemotherapy protocol (63.6%). The initial dose of ibrutinib for CLL was 420 mg/day in all patients. In both groups, patients with CLL, and other B-cell lymphomas, ibrutinib was used as a single agent with no addition of other treatment agents. The patients with CLL were on ibrutinib for a median of 4 months (range, 2–18). The mean lymphocyte count at the initiation of treatment with ibrutinib decreased from 38,200×103/mL to 3,900×103/mL at the end of the 12th month of treatment. The lymphocyte counts in regard to time are shown in Fig. 1. Treatment-emergent adverse events such as lymphocytosis had developed in 2 patients. The incidence of adverse events (grade 3 or 4) was 36.4%. Adverse events during treatment with ibrutinib are listed in Table 2. None of the patients required dose reduction. Diarrhea (any grade) was reported in 3 (27.3%) patients, and pneumonia (any grade) occurred in 3 (27.3%) patients. Two (18.2%) patients had thrombocytopenia (any grade) and/or neutropenia. Hematological toxicity (grade≥3) was not reported in any patient. The treatment was discontinued in 4 (45.5%) patients: due to adverse events of grade 4 in 3 patients, and disease progression in 1 patient. In the final response assessment during ibrutinib treatment, the ORR was 85.6% [28.5% complete response (CR) and 57.1% partial response (PR)]. Although the median OS had not yet been reached even after ibrutinib treatment (Fig. 2), the median PFS was 12.93 months [95% confidence interval (CI), 6.93–18.89].

Table 1

Demographic and clinical features of the patients with CLL.

Demographic and baseline clinical featuresN=11 (%)
Gender, female/male (%)4/7 (36.4/63.4)
Age, median (range)65 (51–80)
ECOG performance score≥3 1 (9.1)
Bulky lesion, N (%) 2 (18.2)
Rai stage≥3, N (%) 7 (63.6)
Del17p, N (%) 4 (36.4)
N of previous treatments
0–1 5 (45.5)
2–3 4 (36.4)
>3 2 (18.1)
Previous treatment regimens
R-FC 7 (63.6)
R-CVP 4 (36.4)
R-bendamustin 3 (27.3)
Chlorambucil 2 (18.2)
Other 4 (36.4)
Treatment duration with ibrutinib (mo, median) 4 (2–18)
Side effects of grade≥3 during treatment with ibrutinib 4 (36.4)
Treatment-emergent lymphocytosis, N (%) 0 (0.0)
Hb≤11 (g/dL), N (%) 6 (54.5)
Platelet≤100×109/L, N (%) 7 (63.6)
WBC (103/mL), mean (range)47,236 (1,300–182,900)
Absolute lymphocyte count (103/mL), mean (range)38,200 (300–166,200)


Table 2

Incidence of adverse events (AEs) in patients with CLL and NHL.

CLLNHL
Hematologic AEsGrade 3–4, N (%)Any grade, N (%)Grade 3–4, N (%)Any grade, N (%)
Anemia0 (0)1 (9.1)0 (0)0 (0)
Thrombocytopenia0 (0)2 (18.1)1 (4.8)2 (9.5)
Neutropenia0 (0)2 (18.1)1 (4.8)1 (4.8)
Lymphocytosis0 (0)2 (18.1)0 (0)2 (9.5)
Non-hematologic AEs
Diarrhea1 (9.1)3 (27.3)2 (9.5)8 (38.1)
Pneumonia3 (27.3)3 (27.3)1 (4.8)5 (23.8)
Hemorrhage0 (0)1 (9.1)0 (0)0 (0)
Atrial fibrillation0 (0)0 (0)0 (0)0 (0)


Figure 1. Relationship between treatment duration and lymphocyte count.

Figure 2. Kaplan-Meier survival curves of overall survival based on del17p mutation in patients with CLL.

Among the 21 patients with B-cell lymphoma, 12 (57.1%) were male and their median age was 69 years (range, 53–84). The demographic and clinical characteristics of the patients are summarized in Table 3. The following number of patients received ibrutinib among the types of lymphoma and were evaluated during follow-up: 7 (33.4%) with MCL, 5 (23.8%) with DLBCL, 4 (19.0%) with MZL, 3 (14.3%) with WM, and 2 (9.5%) with FL. The outcome score [International Prognostic Index (IPI), Follicular Lymphoma International Prognostic Index (FLIPI), MCL International Prognostic Index (MIPI), International Prognostic Scoring System for WM (IPSSWM)] specific to the types of lymphoma, was calculated for each patient. Fourteen (66.7%) patients were in the high-risk group. The ECOG performance score was ≥3 in 8 (38.1%) patients. Four (19.0%) patients had bulky lesions (>6 cm). Twenty (95.2%) patients had advanced- stage disease (stage 3 or 4) when the treatment with ibrutinib was initiated. Ten (47.6%) of these patients had B symptoms. None of these patients had received ibrutinib as first-line therapy. Before initiating treatment with ibrutinib, 9 (42.9%) patients received one step-treatment, 9 (42.9%) patients received two step-treatment, and 3 (14.2%) patients received three steps of treatment. Autologous stem cell transplantation was performed in 1 patient (4.8%). The most commonly administered chemotherapy protocol was rituximab, cyclophosphamide, doxorubicin/daunorubicin hydrochloride, oncovin (vincristine), and prednisone (R-CHOP) (95.2%). Radiotherapy was administered to 1 patient (4.8%) before the treatment. Patients with WM received 420 mg/day, and other patients received 560 mg/day of ibrutinib. The median treatment duration with ibrutinib was 4 months (range, 1–28). In the final response assessment during ibrutinib treatment, the ORR was 66.6% (20.0% CR and 46.6% PR). Two (9.5%) patients experienced treatment-emergent adverse drug event such as lymphocytosis. The most common side effect was diarrhea, noted in 8 (38.1%) patients. Pneumonia (any grade) occurred in 5 (23.8%) patients. Among the side effects that were evaluated, side effects of grade 3 or 4 were observed in 5 (23.8%) patients, and dose reduction was required in 3 (14.3%) patients. The treatment was discontinued in 2 (9.5%) patients due to side effects of grade 4, and in 1 (4.8%) patient due to disease progression. The median OS and PFS had not been reached following ibrutinib treatment (Fig. 3).

Table 3

Demographic and clinical features of patients with NHL.

Demographic and baseline clinical featuresN=21 (%)
Gender, female/male, N (%)9/12 (42.9/57.1)
Age, median (range) 69 (53–84)
Types of NHL
Mantle cell lymphoma, N (%) 7 (33.4)
Diffuse large B-cell lymphoma, N (%) 5 (23.8)
Marginal zone lymphoma, N (%) 4 (19.0)
Waldenström macroglobulinemia, N (%) 3 (14.3)
Follicular lymphoma, N (%) 2 (9.5)
High prognosis score, N (%) 14 (66.7)
ECOG performance score≥3, N (%) 8 (38.1)
Bulky lesion, N (%) 4 (19.0)
Ann Arbor stage≥3, N (%) 20 (95.2)
Presence of B symptoms, N (%) 10 (47.6)
N of previous treatments
1 9 (42.9)
2 9 (42.9)
3 3 (14.2)
Previous treatment regimens
R-CHOP/CHOP 20 (95.2)
R-bortezomib/bortezomib 5 (23.8)
R-CVP/CVP 3 (14.2)
Diğer 7 (33.4)
Treatment duration with ibrutinib, median (range) 4 (1–28)
Patient requiring dose reduction, N (%) 3 (14.3)
Side effect of grade≥3 during treatment with ibrutinib 5 (23.8)
Treatment-emergent lymphocytosis, N (%) 2 (9.5)
Hb (g/dL), median (range)11.8 (7.6–14.6)
Platelet (103/mL), median (range)165,000 (16,000–492,000)
WBC (103/mL), median (range)8,400 (3,200–157,800)
LDH U/L, median (range)257 (105–437)
Creatinine clearance (mL/min/1.73 m2), median (range) 64 (26–120)


Figure 3. Kaplan-Meier survival curves of overall survival in patients with NHL.
DISCUSSION

Ibrutinib, the first oral BTK inhibitor is indicated for several B-cell lymphomas, especially in MCL and CLL. Among the 32 patients in this study, 11 had CLL, 7 had MCL, 5 had DLBCL, 4 had MZL, 3 had WM, and 2 had FL. Previous studies have mostly focused on the disease, whereas this study included all patients prescribed ibrutinib regardless of their diagnosis. Patients with CLL and other lymphomas were evaluated as separate groups.

CLL is more common in old age and among males [20]. In our study, the median age was 65 years (range, 51–80), and the percentage of male patients was higher than that of the female patients. Earlier, cytotoxic agents have been used as first-line treatment for CLL, leading to serious morbidity and mortality in the elderly population [21]. The efficacy and safety of ibrutinib have been demonstrated in several studies that included all age groups of patients with CLL who were either treatment-naive or had received multiple regimens of ibrutinib [22, 23]. In our study, all but one patient had used ibrutinib earlier at stage 2 of the disease. In addition to ibrutinib treatment in advanced stages, the rate of del17p mutation, an indicator of poor prognosis in CLL, was 36.4% among our patients. The median treatment duration with ibrutinib was 4 months (range, 2–18); however, the ORR was 85.6% (28.5% CR and 57.1% PR) in the final response assessment. The follow-up period was not long enough; however, the treatment appeared to be very successful. Similar to the results of our study, ORR was 84% (61% PR, 20% PR-L, 3% CR) in a study with a median follow-up period of 10.2 months [24]. A study with a longer follow-up period showed that the rate of CR and ORR increased as the treatment duration increased [25]. As the follow-up period was not long enough in our study, the median OS had not yet been reached, and the median PFS was 12.93 months.

Ibrutinib is indicated for CLL as well as for many B-cell lymphomas [26-29]. Among all the patients, 95.2% of the patients were in the advanced stage (stage 3–4), and had relapsed/refractory disease. The ORR in our patients with resistant and advanced disease was 66.6% (20.0% CR and 46.6% PR). Wang et al. [30] found similar results in their studies on patients with refractory/relapsed MCL [ORR 68.0%, (21.0% CR and 47.0% PR)]. In other studies, the ORR was 48.0% in patients with MZL, 37.5% in patients with FL, and 90.0% in patients with WM [28, 31, 32]. Response rate and response time in patients with FL were lower than those in patients with CLL, MCL, and MZL [31]. However, the ORR was 82.0% in one study, in which ibrutinib was combined with rituximab in treatment-naive patients with FL [33]. The median OS and PFS had not yet been reached because of the short follow-up period in our study.

We believe that the treatment algorithms might continue to evolve rapidly in several diseases thanks to ibrutinib treatment. The treatment can be administrated in early stages, especially in treatment-naive patients, if the efficacy of ibrutinib is clear [21]. This is very important in fragile and older patients who cannot tolerate cytotoxic therapy [22].

Ibrutinib is easy to use and is generally well-tolerated. However, the most common side effect is diarrhea (48–50%) [23, 25]. In our study, the incidence of diarrhea was 27.3% in patients with CLL, and 38.1% in patients with other B-cell lymphomas. The risk of infections associated with the disease increases in CLL and other B-cell malignancies [34]. Patients with CLL are predisposed to infections, due to hypogammaglobulinemia, dysfunction of the complement system, and impairment of neutrophil function and cellular immunity [35]. Additionally, we believe that the administered treatments, especially cytotoxic therapy, would contribute to these situations. Infection is the most important cause of hospitalization, morbidity, and mortality in patients with CLL [36]. For these reasons, all patients were administered trimethoprim/sulfamethoxazole as a prophylactic treatment against Pneumocystis jirovecii pneumonia, and valaciclovir was administered to prevent herpes re-infection. Besides, intravenous immunoglobulin was administered to patients with CLL, if the IgG (immunoglobulin G) level was <500. The studies that compare ibrutinib with ofatumumab and chlorambucil in terms of risk of infection (≥grade 3), showed that the risk increased minimally with no significant increase [6, 22]. In our study, pneumonia developed in 27.3% of the patients with CLL, and 23.8% of the patients with other B-cell lymphomas. Pneumonia, disease progression, or death were the most important reasons for discontinuation or withdrawal of the treatment. It has been shown that the dose reduction of ibrutinib due to adverse events in patients with CLL, has no effect on the OS [37]. However, it has been reported that the incidence of side effects decreases as the treatment duration with ibrutinib increases [23]. In addition, several studies have shown that treatment with ibrutinib increases the number of T-cells and improves their functions, strengthening the immune system; however, the risk of infection is still high during the first year of treatment [38].

Apart from infection, ibrutinib treatment is also associated with side effects, including bleeding, AF, hypertension, and arthralgia [23]. It is shown that the risk of AF increases in patients with a history of AF and increased treatment duration with ibrutinib [39]. In our study, no newly diagnosed cases of AF were observed. However, ibrutinib was initiated in 1 patient who was previously diagnosed with AF with controlled ventricular rate. There was no cardiac rhythm abnormalities in the patient during the treatment. We consider that, having side effects that are predictable such as HT or AF, is not a contraindication for ibrutinib treatment, if these diseases are controlled.

In addition to the above-mentioned side effects, lymphocytosis may be observed in peripheral blood due to the rapid shrinkage of the lymph nodes during ibrutinib treatment. This is temporary and is not associated with disease progression [16]. It peaks at 2–4 weeks, and returns to normal within 6 months of treatment. Besides ibrutinib, this has also been observed during treatment with spleen tyrosine kinase inhibitors and phosphoinositide 3-kinase inhibitors [40, 41]. Lymphocytosis in the peripheral blood was observed in four of our patients during treatment with ibrutinib. The lymphocyte count became completely normal in the second month after continuation treatment. This picture on lymphocytosis should not be misunderstood as improvement; caution should be exercised, especially in patients with CLL.

The most important limitations of our study were that the sample size was small, and median duration of follow-up was short. However, the strength of our study was that it included patients with a wide range of diagnoses. Therefore, we were able to identify the efficacy of ibrutinib in different diagnoses in a short duration of time.

In conclusion, the real-life data from patients with different diagnoses are similar to the results of many other studies on ibrutinib. Ibrutinib is a good treatment option for CLL and other B-cell lymphomas; it has an acceptable side effect profile with high and promising CR/PR rates. Treatment with ibrutinib at an early stage decreases the burden of cytotoxic therapy in fragile patients leading to increased quality of life.

Ethical Statement

The study protocol received approval from the institutional review board, and the personal data of all the patients were secured.

Authors’ Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

References
  1. Melchers F. Checkpoints that control B cell development. J Clin Invest 2015;125:2203-10.
    Pubmed PMC CrossRef
  2. Khan WN. Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase. Immunol Res 2001;23:147-56.
    Pubmed CrossRef
  3. Wiestner A. Targeting B-cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol 2013;31:128-30.
    Pubmed CrossRef
  4. Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet 2012;380:848-57.
    Pubmed CrossRef
  5. Pan Z, Scheerens H, Li SJ, et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem 2007;2:58-61.
    Pubmed CrossRef
  6. Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014;371:213-23.
    Pubmed PMC CrossRef
  7. Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood 2015;126:739-45.
    Pubmed PMC CrossRef
  8. Fowler NH, Advani RH, Sharman J, et al. The Bruton's tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma. Blood (ASH Annual Meeting Abstracts) 2012;120(Suppl):156.
    CrossRef
  9. Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med 2015;372:1430-40.
    Pubmed CrossRef
  10. Denlinger NM, Epperla N, William BM. Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib. Cancer Manag Res 2018;10:615-24.
    Pubmed PMC CrossRef
  11. Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 2015;21:922-6.
    Pubmed CrossRef
  12. Singh J, Petter RC, Kluge AF. Targeted covalent drugs of the kinase family. Curr Opin Chem Biol 2010;14:475-80.
    Pubmed CrossRef
  13. Schmidt U, Boucheron N, Unger B, Ellmeier W. The role of Tec family kinases in myeloid cells. Int Arch Allergy Immunol 2004;134:65-78.
    Pubmed CrossRef
  14. Grabinski N, Ewald F. Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2- positive breast cancer cells. Invest New Drugs 2014;32:1096-104.
    Pubmed CrossRef
  15. McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood 2014;124:3829-30.
    Pubmed CrossRef
  16. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369:32-42.
    Pubmed PMC CrossRef
  17. Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica 2018;103:874-9.
    Pubmed PMC CrossRef
  18. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 2018;131:2745-60.
    Pubmed CrossRef
  19. Cheson BD, Ansell S, Schwartz L, et al. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 2016;128:2489-96.
    Pubmed CrossRef
  20. Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 2011;105:1684-92.
    Pubmed PMC CrossRef
  21. Eichhorst B, Fink AM, Busch R, et al. Chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus bendamustine and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a planned interim analysis of the CLL10 Trial, an international, randomized study of the German CLL Study Group (GCLLSG). Blood (ASH Annual Meeting Abstracts) 2013;122(Suppl):526.
    CrossRef
  22. Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 2015;373:2425-37.
    Pubmed PMC CrossRef
  23. Brown JR, Hillmen P, O'Brien S, et al. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Leukemia 2018;32:83-91.
    Pubmed PMC CrossRef
  24. Winqvist M, Asklid A, Andersson PO, et al. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group. Haematologica 2016;101:1573-80.
    Pubmed PMC CrossRef
  25. Burger JA, Barr PM, Robak T, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia 2020;34:787-98.
    Pubmed PMC CrossRef
  26. Bartlett NL, LaPlant BR, Qi J, et al. Ibrutinib monotherapy in relapsed/refractory follicular lymphoma (FL): preliminary results of a phase 2 consortium (P2C) trial. Blood (ASH Annual Meeting Abstracts) 2014;124(Suppl):800.
    CrossRef
  27. Jeon YW, Yoon S, Min GJ, et al. Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience. Cancer Med 2019;8:6860-70.
    Pubmed PMC CrossRef
  28. Noy A, de Vos S, Thieblemont C, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood 2017;129:2224-32.
    Pubmed PMC CrossRef
  29. Tillman BF, Pauff JM, Satyanarayana G, Talbott M, Warner JL. Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies. Eur J Haematol 2018;100:325-34.
    Pubmed CrossRef
  30. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013;369:507-16.
    Pubmed PMC CrossRef
  31. Bartlett NL, Costello BA, LaPlant BR, et al. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. Blood 2018;131:182-90.
    Pubmed PMC CrossRef
  32. Dimopoulos MA, Trotman J, Tedeschi A, et al. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol 2017;18:241-50.
    Pubmed CrossRef
  33. Fowler N, Nastoupil L, de Vos S, et al. Ibrutinib plus rituximab in treatment-naive patients with follicular lymphoma: results from a multicenter, phase 2 study. Blood (ASH Annual Meeting Abstracts) 2015;126(Suppl):470.
    CrossRef
  34. Wadhwa PD, Morrison VA. Infectious complications of chronic lymphocytic leukemia. Semin Oncol 2006;33:240-9.
    Pubmed CrossRef
  35. Morrison VA. Infectious complications in patients with chronic lymphocytic leukemia: pathogenesis, spectrum of infection, and approaches to prophylaxis. Clin Lymphoma Myeloma 2009;9:365-70.
    Pubmed CrossRef
  36. Molica S. Infections in chronic lymphocytic leukemia: risk factors, and impact on survival, and treatment. Leuk Lymphoma 1994;13:203-14.
    Pubmed CrossRef
  37. UK CLL Forum. Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients. Haematologica 2016;101:1563-72.
    Pubmed PMC CrossRef
  38. Long M, Beckwith K, Do P, et al. Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest 2017;127:3052-64.
    Pubmed PMC CrossRef
  39. Wiczer TE, Levine LB, Brumbaugh J, et al. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. Blood Adv 2017;1:1739-48.
    Pubmed PMC CrossRef
  40. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115:2578-85.
    Pubmed PMC CrossRef
  41. Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110d, for relapsed/refractory chronic lymphocytic leukemia. Blood 2014;123:3390-7.
    Pubmed PMC CrossRef


e-submission

This Article

Current Issue

ba_link01

Indexed/Covered by

Today : 171  /
Total : 254,370